Publication of Suppl.Prospcts

RNS Number : 4181M
Coventry Building Society
16 September 2019
 

NOTICE

 

Publication of Prospectus SUPPLEMENT

 

COVENTRY BUILDING SOCIETY

(the Issuer)

 

The following Prospectus Supplement has been approved by the UK Listing Authority and is available for viewing:

 

Prospectus Supplement dated 13 September 2019 in relation to Coventry Building Society £5 billion Euro Medium Term Note Programme

 

The Prospectus Supplement should be read and construed in conjunction with the Base Prospectus dated 14 February 2019  (together, the "Prospectus").

 

To view the Prospectus Supplement, please paste the relevant URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/4181M_1-2019-9-16.pdf

 

 

The Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

 

For further information, please contact

 

Thomas Crane

General Counsel and Secretary

Coventry Building Society

Telephone: 02476 435506

 

DISCLAIMER - INTENDED ADDRESSEES

 

Please note that the information contained in the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the relevant Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the relevant Prospectus is not addressed. Prior to relying on the information contained in the relevant Prospectus you must ascertain from the relevant Prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement. 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PSPEAXNKFAKNEEF
UK 100